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Introduction 
Fast growing cancers such as malignant brain tumors, for 
instance, can attack the brain and the spinal cord in rapidly1-
4. They attack the central nervous system and leave patients 
with inferior prognosis. A patient with glioblastoma, for 
instance, will have a six-percentage chance for a five-year 
survival rate. The options for most patients with a brain 
tumor or a localized tumor is debulking surgery, followed by 
radiation or chemotherapy. In this context, the use of 
chemotherapy is inevitable for most patients, and as 
research literature note, issues of multidrug resistance and 
cytotoxicity go hand in hand with the treatment. Cytotoxic 
drugs also called as cytostatic are drugs that target cancer 
cells. These drugs aim to inhibit cell division, and in this way, 
they lead to the death of cancer cells5-10. Their capability to 
destroy tumors results in better outcomes for patients after 
their debulking surgeries. The drugs are not only useful for a 
primary tumor but also can be rendered for destroying 
smaller tumors. The problem with the drugs is that they 
affect all other healthy cells as well, although they are 
particularly sensitive to cancer cells. Medications are often 
delivered as either high dosage drugs for some aggressive 
cancers or as a combinatorial therapy11-15. 
Sun et al.16 discuss how the co-delivery of dual-drugs with 
nanoparticle can help prevent multidrug resistance MDR in 
cancer patients. Chemotherapy plays a very vital role when 
it comes to treating different types of cancer. However, many 
of the existing treatments are problematic in themselves 
because they are either cytotoxic and hence cause ill-health 
of the patient or in some situations could provoke multi-
drug resistance17-20. The drugs that target the tumor cells 
will also affect the healthy tissues. In the case of MDR, the 
tolerance barrier has to be crossed by introducing more 
amount of the drug to treat the cancer patient, and this, in 
turn, contributes to increased cytotoxicity21-24.  
 
 
Figure 1: Co-delivery for achieving reversal of MDR, the core 
matched nano-emulsions are co-delivering PTX and 5-FU for 
achieving reversal of multidrug-resistance16,25. 
Kang et al.15 presented a conjugate drug, and the 
camptothecin CPT loaded on a nanoparticle as the answer to 
selectively deliver the drug to the tumor cell. This way the 
healthy cells are not affected. Sun et al. on the other hand, 
present a targeted drug delivery system with dual drugs 
used to combat MDR. In some cases, it is even possible to 
reverse MDR through nano drug co-delivery mechanism as 
presented in the above diagram that highlights how Nano-
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emulsions are co-delivering PTX and 5FU to achieve the 
reversal of MDR16,26,27. 
Sun et al.16,25 in their review identified that the use of 
multiple drugs as chemotherapeutic agents did provide 
some efficacy in the context of treating cancer. It did reduce 
multidrug resistance as well because various medications 
have different pharmacokinetic properties. However, the 
efficacy observed was very nominal. It was identified that 
the use of different drugs, with nanotechnology, gene 
engineering, and associated significant data insights, shows 
much more promise. Improving the anticancer index is 
possible. Nanoparticle drug delivery system has the 
capability of selectivity in targeting tumor regions. An 
important adverse effect in radiation and chemotherapy was 
the loss of healthy cells25,28-30. Healthy cells also absorb the 
drug and are led to apoptosis. In the case of selective 
targeting, as is observed in the case of a nanoparticle drug 
delivery system, the healthy cells are spared, and hence the 
cytotoxicity effect is reduced. MDR problems are overcome 
as the nanotechnology carefully protects the payload31-33. 
The payload is usually a combination of chemotherapeutic 
drugs and an MDR sensitizer that reduces MDR effects. The 
nanotechnology capability is what helps encapsulate the 
drug and the inhibitor and helps deliver them in one shot34-
36.  
The work aim was to review Nanoparticle drug delivery for 
reducing cytotoxicity and MDR risks to cancer patients. The 
work identified how in the context of cancer treatment, 
especially in the case of fast-growing cancer, and other 
malignant brain tumors, the use of chemotherapeutic agents 
are inevitable. Even with debulking surgeries, the patient 
has to undergo a regime of radiation or delivery of drugs. It 
is in this context that secondary health issues arise for the 
patient, such as cytotoxicity of drugs which harms their 
health or multidrug resistance that they develop which will 
stop the efficacy of their treatment drug action. 
Nanotechnology-based drug delivery systems were 
identified to hold much promise for preventing cytotoxicity 
and for MDR.  
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